UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 30, 2012
Date of report (Date of earliest event reported): August 2, 2012
GENTA INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
	Delaware
	(State or Other Jurisdiction of Incorporation)
0-19635		33-0326866
(Commission File Number)		(IRS Employer Identification No.)
200 Connell Drive Berkeley Heights, NJ		07922
(Address of Principal Executive Offices)		(Zip Code)
	(908) 286-9800
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o Pre -commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o Pre -commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On ~~July~~August 302, 2012, Genta Incorporated (the “Company”), ~~announced~~intends ~~that~~to itfile ~~has~~a ~~received~~voluntary ~~formal~~petition ~~notice~~for ~~from~~relief under Chapter 7 of the ~~drug~~United ~~regulatory~~States ~~authority~~Bankruptcy ofCode (the ~~People’s~~“Code”) ~~Republic~~in the United States Bankruptcy Court for the District of ~~China~~Delaware (~~SFDA~~the “Filing”). Upon ~~that~~the Filing, a Chapter 7 trustee will assume control of the Company ~~has~~and ~~received~~the ~~approval~~assets toof ~~start~~the ~~clinical~~Company ~~trials~~will ~~with~~be ~~tesetaxel,~~liquidated ~~its~~in ~~lead~~accordance ~~clinical~~with ~~compound,~~Chapter in7 ~~China~~of the Code.

~~SFDA~~Further ~~has~~information ~~requested~~will ~~and~~be ~~approved~~provided afollowing ~~dose-ranging study of~~ the ~~combination of capecitabine plus tesetaxel, up to and including the dose used in a pivotal randomized trial (known as TESEGAST), as well as subsequent participation by China in the TESEGAST study~~Filing. The TESEGAST study is designed to evaluate the safety and activity of tesetaxel plus capecitabine compared with capecitabine plus placebo in patients with advanced gastric cancer. Gastric cancer is the second most common tumor type in China.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Upon the Filing, the officers will be terminated, and the directors will resign effective immediately upon the Filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		GENTA INCORPORATED
Date:	~~July~~August 302, 2012	By:	/s/ GARY SIEGEL
			Name:	Gary Siegel
			Name: Gary Siegel
			Title:	Vice President, Finance

Filing Compare · GENTA INC DE/